Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Core Insights - Tevogen Bio Holdings Inc. has made significant advancements in its PredicTcell™ platform, which aims to enhance precision immunotherapy through advanced machine learning and transformer-based models, supported by Microsoft and Databricks [1][3] Development Progress - The alpha version of PredicTcell was trained on over 124,000 records with transformer-based architecture and 91,000 records using traditional machine learning, achieving recall levels of approximately 92–97% and precision between 38–43% [2] - The beta version has expanded its training dataset to around 1.4 million records, with a total dataset exceeding 6.7 billion records, significantly increasing the number of features for training from 22 to 27 [5][6] Clinical Implications - The advancements in the PredicTcell platform could lead to T-cell therapies that reliably bind to their target, potentially transforming clinical success rates and reducing drug development costs [3][6] - Insights from Tevogen's ExacTcell™ platform and positive Phase 1 trial results inform the beta version's focus on higher precision in identifying virology targets [3] Market Potential - The company aims to raise efficacy standards in T-cell therapies, unlock new markets in immunotherapy, and improve patient access to life-saving therapies across various diseases, including infectious diseases and oncology [3][6]